FDA
-
-
-
-
-
-
-
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
-
-
-
-
-
-
-
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
TuHURA Biosciences (HURA) Says FDA Removed Partial Clinical Hold on Phase 3 Accelerated Approval Trial for IFx-2.0
-
-
-
-
-
-
-
TuHURA Biosciences (HURA) Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda in First Line Treatment for MCCUP
-
-
-
-
-
-
-
TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics
322,243 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

